Does Treating Undifferentiated Arthritis Delay RA Development?
The primary outcome was development of rheumatoid arthritis.
Year In Review Rheumatoid Arthritis
Enbrel Mini With AutoTouch Now Available
The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker.
Sarilumab Examined for Effects on Physical Function in RA
Sarilumab administered every 2 weeks is associated with similar improvements in physical function in adult patients with rheumatoid arthritis, compared with adalimumab.
Anti-Inflammatory Foods May Help With RA Symptoms, Progression
Specific foods that were highlighted include dried plums, blueberries, pomegranates, whole grains, ginger, turmeric, specific oils, and teas; these foods were found to reduce inflammatory cytokines, joint stiffness, pain, and oxidative stress.
Factors Associated With Successful Biologics Tapering in RA
There were also significant differences between the groups in concomitant oral corticosteroid use (43.1 vs. 34.8% in the stable treatment and DT groups, respectively) and CRP level (1.9±2.5 vs. 1.1±1.3 respectively).
Certain Medications Linked to Increased Osteoporotic Fracture Risk
The National Data Bank for Rheumatic Diseases was assessed and found to include 11,002 RA patients, these were then followed for a median of 5.4 years.
Temporary Methotrexate Cessation Ups Flu Vaccine Efficacy in RA Patients
Findings in patients with rheumatoid arthritis taking a stable dose of methotrexate
Can Anemia Predict Radiographic Progression in Tofacitinib Treated RA Patients?
In this post hoc analysis, researchers explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.
Discontinuation Rates Examined After Switch to Biosimilar
Study authors aimed to assess the pharmacokinetics, efficacy, immunogenicity, safety, and drug discontinuation after switching from infliximab (Remicade) to the biosimilar CT-P13 in 192 patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis in daily practice.
Long-Term Effectiveness of Adalimumab Examined in RA
The authors reported that of the patients who continued taking adalimumab for ≥1 year, 67.0% were considered in low disease activity (LDA)/remission (CDAI ≥10).
